# Understanding and Managing Side Effects of Bispecific Antibody Therapy for Multiple Myeloma: What Patients Should Know

Bispecific antibodies (BsAbs) represent a major advancement in treating relapsed/refractory multiple myeloma (RRMM), offering high response rates even in heavily pretreated patients, but they come with complex side effects and operational challenges. This study, based on interviews with 10 hematologists/oncologists from academic and community practices, found that cytokine release syndrome (CRS) is the most common acute toxicity — generally mild and manageable with early use of tocilizumab — while infections from immune suppression are the most significant long-term concern. The research highlights that successful treatment depends on multidisciplinary care teams, standardized side-effect protocols, infection prevention strategies, and strong collaboration between academic and community cancer centers to ensure patients can safely access these transformative therapies.

# Understanding and Managing Side Effects of Bispecific Antibody Therapy for Multiple Myeloma: What Patients Should Know

## Table of Contents

- Key Points
- Why This Research Matters: The Challenge of Relapsed/Refractory Multiple Myeloma
- How the Study Was Conducted
- Finding 1: Doctors View Bispecific Antibodies as Highly Effective in Late-Stage Disease
- Finding 2: Choosing the Right Treatment and Timing Remains Challenging
- Finding 3: Managing Short-Term Side Effects: CRS and ICANS
- Finding 4: Long-Term Side Effects and Staying on Therapy
- Finding 5: Practical Barriers to Getting Treatment
- Finding 6: How Academic and Community Centers Work Together
- What This Means for Patients
- Study Limitations
- Recommendations for Patients and Families
- Frequently Asked Questions
- Source Information

## Key Points

- In interviews, ten blood cancer specialists described bispecific antibodies as effective for relapsed/refractory multiple myeloma, including disease resistant to three major drug classes.
- Those specialists said cytokine release syndrome was the most common short-term side effect, usually mild and manageable with early tocilizumab, often during step-up dosing.
- They described infections from immune suppression as the most challenging long-term concern, reduced but not eliminated by IVIG, antiviral, and PJP prophylaxis.
- The same specialists said successful treatment depends on multidisciplinary teams, standardized side-effect protocols, and collaboration between academic and community cancer centers.
- This was a qualitative study of ten physicians based on a preprint not yet peer reviewed, so findings reflect their experiences and should not guide individual treatment decisions.

## Why This Research Matters: The Challenge of Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of plasma cells — a type of white blood cell that normally produces antibodies to fight infection. Despite major advances in treatment, myeloma is still considered an incurable disease. Even with aggressive first-line regimens that combine proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies, most patients eventually experience a relapse (the cancer returns).

The numbers tell an important story about the gap between clinical trials and real-world experience. Recent phase 3 clinical trials report 5-year overall survival rates exceeding 70% in carefully selected trial populations. However, population-based estimates — which reflect what actually happens in everyday medical practice — remain closer to 60%. This gap underscores the difference between ideal trial conditions and real-world care.

Outcomes are particularly poor in patients with relapsed/refractory multiple myeloma (RRMM) — meaning the cancer has returned and has become resistant to treatment. Patients who have become resistant to all three major drug classes face an especially urgent need for novel treatment approaches.

## How the Study Was Conducted

This was a qualitative study conducted by Medlive — A PlatformQ Health Brand, a medical education company. Researchers used semi-structured interviews (conversations guided by prepared questions but allowing open discussion) and thematic analysis to explore how bispecific antibodies are actually used in real-world practice.

Ten hematologists/oncologists (blood cancer specialists) participated in the study. Of these, 4 worked in academic medical centers and 6 worked in community-based practices. All had direct experience prescribing bispecific antibodies or managing patients undergoing this therapy. Interviews were conducted between November 2024 and May 2025, lasting approximately 45–60 minutes each, and were audio-recorded with participant consent. Recordings were professionally transcribed word-for-word for qualitative analysis.

The interview guide focused on four core areas:

1. Patient selection criteria and treatment sequencing (which patients get which treatment, and in what order)
1. Toxicity monitoring and management strategies, including CRS and ICANS
1. Operational models for therapy delivery, such as inpatient versus outpatient ramp-up (the gradual dose increase at the start of treatment) and academic–community referral structures
1. Barriers and solutions related to long-term treatment access, equity, and sustainability

Representative interview questions included: "What is your experience managing patients with RRMM with bispecific antibodies?" "What is your preferred bispecific antibody to manage RRMM? What drives your selection?" "Is your practice equipped to treat patients with bispecific antibodies, or do you routinely refer patients to an academic center?" "How do patients know what adverse events to look for, when to contact someone, and who to contact?" and "Who monitors for CRS (during step-up dosing and subsequent doses)? Has the monitoring and management of CRS been challenging at your practice?"

## Finding 1: Doctors View Bispecific Antibodies as Highly Effective in Late-Stage Disease

A consistent theme across all interviews was that bispecific antibodies provide meaningful clinical benefit for patients with relapsed/refractory multiple myeloma who have exhausted other treatment options. Doctors described these agents as highly effective across multiple lines of therapy — including in patients whose cancer is triple-class refractory (resistant to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies).

The ability of these agents to induce remissions in patients with limited alternatives was a recurring point of emphasis. One physician stated: "Bispecific antibodies produce high response rates even in triple-class refractory patients." Another noted, "They stand out from many other options in the relapsed/refractory setting." A third doctor observed that "response can occur pretty quickly, and it deepens over time." Perhaps most tellingly, one participant said, "This class is extremely promising and should be made accessible to as many patients as possible."

What makes bispecific antibodies different? These are engineered proteins that work by simultaneously targeting two things: CD3-expressing T cells (the immune system's killer cells) and tumor-associated antigens on myeloma cells — most commonly B-cell maturation antigen (BCMA) or G protein–coupled receptor class C group 5 member D (GPRC5D). By grabbing both at once, they redirect the body's own immune system to attack and destroy malignant plasma cells.

## Finding 2: Choosing the Right Treatment and Timing Remains Challenging

One of the most significant challenges doctors face is choosing which bispecific antibody to use and when. There are currently no direct head-to-head comparison studies between BCMA-targeting and GPRC5D-targeting agents, so treatment selection is largely empirical (based on experience and judgment rather than direct comparative evidence).

Clinicians described these decisions as highly individualized and frequently requiring multidisciplinary input. One doctor captured the dilemma: "We're in this conundrum of trying to figure out how best to sequence therapies and identify the appropriate patient." Another described their group's rigorous approach: "We have a ten-physician group, and all BsAb patients are discussed at tumor board."

Treatment decisions often hinge on previous therapy exposures or planned transitions to other treatments. For example, some centers use GPRC5D bispecific antibodies to stabilize disease before administering BCMA-targeted CAR T-cell therapy (a treatment where a patient's own immune cells are collected, genetically modified, and reinfused to attack the cancer). As one doctor explained: "There are patients who may have seen BCMA-targeted therapy beforehand, so if we know they've been exposed, we pivot to GPRC5D-targeting agents." Another noted, "A lot of selection is about prior therapy and the goal of using the bispecific."

Multidisciplinary case discussions, including tumor boards, were described as central forums for aligning treatment strategy across care teams. This lack of comparative data presents one of the most significant clinical challenges in the field today.

## Finding 3: Managing Short-Term Side Effects: CRS and ICANS

Doctors across all interviews described the acute (short-term) side effects of bispecific antibodies as expected and largely "front-loaded" — meaning they most commonly occur during step-up dosing (the gradual dose increase given at the start of treatment) or early in the treatment course.

### Cytokine Release Syndrome (CRS): The Most Common Acute Side Effect

Cytokine release syndrome (CRS) was consistently described as the most frequently encountered acute toxicity. CRS happens when the activated immune cells release a flood of inflammatory proteins (cytokines) into the bloodstream, causing fever, chills, low blood pressure, and sometimes difficulty breathing. The good news: participants noted that CRS events were predominantly low grade (mild) and occurred early in treatment.

Doctors described established institutional protocols and multidisciplinary team involvement as central to managing CRS. Early recognition and timely intervention — including the use of tocilizumab (a medication that blocks cytokine signaling) — were common elements of the approach. One physician noted: "CRS is expected, but it's usually mild and very manageable if you intervene early." Another said, "We're seeing almost all grade 1 CRS, managed easily with tocilizumab."

Notably, some academic programs now use prophylactic tocilizumab (giving the medication preemptively to prevent CRS) in outpatient settings, which has helped enable outpatient step-up dosing.

### ICANS: Less Common But Requiring Heightened Vigilance

In contrast to CRS, immune effector cell–associated neurotoxicity syndrome (ICANS) — a condition that can cause confusion, difficulty speaking, tremors, or other neurological symptoms — was described as less common but requiring extra attention. Participants emphasized the importance of early detection strategies, including close neurological monitoring and staff awareness, particularly during initial dosing periods.

Ongoing team education and case review, including tumor boards, were described as critical mechanisms for reinforcing recognition of acute toxicities and maintaining operational readiness. As one participant said, "We host myeloma tumor boards and case reviews to keep education ongoing." Early recognition and caregiver support were highlighted as the best ways to mitigate ICANS risk.

## Finding 4: Long-Term Side Effects and Staying on Therapy

While acute side effects get the most attention, doctors consistently described chronic (long-term) side effects as the key factor determining whether patients can stay on bispecific antibody therapy over the long haul.

### Infections: The Most Persistent Concern

Infection risk was highlighted as the most challenging aspect of long-term treatment. Because bispecific antibodies targeting BCMA deplete plasma cells — including healthy ones that produce protective antibodies — patients often develop hypogammaglobulinemia (low levels of immunoglobulin antibodies in the blood), which increases susceptibility to infections.

Crucially, doctors noted that infections occurred even when patients did not have low neutrophil counts (neutropenia). One physician explained: "Infectious disease is the most challenging to manage… even if they're not neutropenic." This reflects cumulative immune dysfunction related to both prior therapies and ongoing plasma cell depletion.

Supportive strategies such as intravenous immunoglobulin (IVIG) — infusions of antibodies collected from healthy donors — were commonly employed. However, doctors emphasized that these measures reduced but did not eliminate infection risk. As one participant put it: "IVIg significantly reduces infection rates but does not eliminate them."

Standard prevention measures mentioned by clinicians included:

- Antiviral prophylaxis (medications to prevent viral infections)
- Pneumocystis jirovecii pneumonia (PJP) prophylaxis (medication to prevent a serious type of pneumonia)
- Intravenous immunoglobulin (IVIG) replacement therapy
- Regular monitoring of immunoglobulin levels

### Cytopenias: Low Blood Counts Requiring Active Management

Cytopenias (low blood cell counts) were described as another frequent and ongoing challenge. Neutropenia (low neutrophil count, which increases infection risk) was the most commonly cited hematologic toxicity. Doctors noted using growth factor support (medications that stimulate the bone marrow to produce more white blood cells) and close monitoring over time to allow patients to continue therapy.

One clinician offered a helpful perspective: "Cytopenias are more likely in patients with high disease burden but tend to resolve over weeks to months." This suggests that while blood count suppression can be challenging early in treatment, it often improves with time.

### GPRC5D-Specific Side Effects: Skin, Nail, Mouth, and Taste Changes

Doctors also discussed toxicities specific to GPRC5D-targeted bispecific antibodies. These include dermatologic (skin) reactions, nail changes, oral (mouth) issues, and taste-related adverse effects that can affect quality of life and nutritional status. One participant summarized: "GPRC5D bispecifics cause more skin, nail, taste, and mucosal toxicities, affecting quality of life."

These side effects were characterized as distinct from those seen with BCMA-directed agents. They typically require patient counseling and supportive care rather than acute intervention — but they significantly contribute to considerations around long-term treatment tolerability.

## Finding 5: Practical Barriers to Getting Treatment

Operational barriers were described as major determinants of whether bispecific antibodies could be initiated and managed locally — a theme raised by all 10 of 10 participants. For patients, this directly affects how quickly they can access treatment and how convenient that treatment will be.

### Challenges in Community Settings

Community clinicians frequently described several obstacles:

- Limited hospital support or pathways for step-up dosing (observation/admission capacity, staffing, and training requirements)
- Reliance on referral centers for treatment initiation
- Referral capacity constraints (consult backlogs or treatment quotas at academic centers)
- Formulary and pharmacy committee processes for approving new agents
- Financial sustainability challenges for ramp-up dosing (the cost of the medication during the dose escalation phase)

One doctor explained: "The reason that we haven't started our own is because there's a lack of operational support from the hospital." Another described the approval hurdle: "Each medicine has to go before a pharmacy committee… we have to justify why we want to include it versus something else."

### Electronic Health Record Fragmentation

A particularly notable barrier — raised by 10 of 10 participants — was electronic health record (EHR) fragmentation. When community and academic centers use different, non-interoperable EHR systems, it complicates shared care and timely awareness of dosing and supportive care plans. One participant described the frustration: "I have maybe a handful of contacts where I feel like communication flows well, but it's never perfect because we're in a different EHR system."

### Inpatient vs. Outpatient Step-Up Dosing

Participants described substantial variability in where and how step-up dosing was delivered. Some academic programs have moved portions of step-up dosing into outpatient infusion settings, supported by trained nursing teams, rapid response pathways, and ready access to tocilizumab. One doctor noted, "We now routinely do outpatient ramp-up with prophylactic tocilizumab." Others continue to rely primarily on inpatient admission or observation beds.

The decision about inpatient versus outpatient initiation was described as individualized and commonly informed by social support availability, travel distance, and the patient's baseline medical conditions. Community clinicians expressed growing interest in developing local step-up dosing programs but noted that implementation requires internal multidisciplinary planning (involving pharmacy, nursing, neurology, pulmonary/critical care) and recurring education to maintain team readiness.

Administrative details — such as inpatient drug cost attribution, local formulary status, and the ability to transmit records efficiently — were described as influencing whether treatment initiation could occur locally or required referral to a larger center.

## Finding 6: How Academic and Community Centers Work Together

Given these barriers, academic-community collaboration is essential — a theme raised by all 10 of 10 participants. Doctors described two main shared-care models:

-
**Hub-and-spoke model:** Academic centers perform step-up dosing and early-cycle monitoring, then transition maintenance dosing to the patient's local oncologist.
-
**Co-management model:** The initiating (academic) center remains involved through periodic reassessment, telemedicine check-ins, or on-demand toxicity consultation.

One community doctor described their experience: "We don't do the loading doses here; we send them to [an urban hospital]. Once they're through loading, I take care of them locally." Another noted that "clear handoffs after cycle 1 and ongoing academic support help build confidence."

Effective handoffs require clear documentation of dosing schedules and supportive care plans, direct clinician-to-clinician communication, and predefined escalation pathways back to the initiating center for acute toxicities or complex infections. The content of handoffs commonly included:

- Dosing calendars
- Infection prophylaxis plans (including immunoglobulin monitoring and replacement thresholds)
- Criteria for dose holds (temporarily pausing treatment)
- Criteria for emergency evaluation or re-referral

However, the quality of communication varied significantly. Some community clinicians reported receiving formal verbal and written signoffs and access to standardized protocols, while others experienced limited documentation or delayed communication — particularly when patients interacted with multiple referral centers or when EHR systems were not interoperable. One participant expressed deep frustration: "If they go to other centers, I hear nothing. It's very frustrating."

Participants also noted variation across centers in supportive care practices (e.g., infection workup pathways and prophylaxis details), which could complicate co-management when patients transitioned between sites.

## What This Means for Patients

For patients with relapsed/refractory multiple myeloma considering bispecific antibody therapy, these findings carry several important messages.

First, bispecific antibodies are genuinely effective — even in patients who have run out of other options. The doctors interviewed were unanimous in their enthusiasm for these agents, describing high response rates in triple-class refractory disease and noting that responses can occur quickly and deepen over time.

Second, side effects are common but manageable. The most frequent acute side effect, CRS, is usually mild and can be effectively treated with tocilizumab — increasingly even given preventively in outpatient settings. While infections are a serious long-term concern, proactive use of IVIG, antiviral medications, and PJP prophylaxis can substantially reduce — though not eliminate — the risk.

Third, the system for delivering this therapy is still evolving. Depending on where you live and which center you receive care at, you may need to travel to an academic center for the initial step-up dosing phase (which typically involves several weeks of gradually increasing doses with close monitoring) before transitioning back to your local oncology team for ongoing maintenance doses.

Fourth, communication between your cancer centers matters. The study found that breakdowns in communication — often due to incompatible electronic health record systems — can complicate shared care. As a patient or caregiver, you can help by actively facilitating communication: asking for written summaries of your treatment plan, confirming your local doctor receives your dosing calendar and infection prophylaxis plan, and understanding the escalation pathway — exactly who to call and when, if you develop symptoms between visits.

## Study Limitations

It is important to understand the limitations of this study. First, it is a qualitative study — meaning it captures the experiences, opinions, and recommendations of 10 clinicians, not quantitative outcome data from a large patient population. The findings reflect the perspectives of these particular physicians, who may not be representative of all practices across the country.

Second, this article is based on a preprint — a research manuscript that has not yet undergone formal peer review. As indicated by the authors, it "should not be used to guide clinical practice" in its current form. The findings are valuable for understanding real-world challenges, but treatment decisions should always be made in consultation with your oncology team based on your individual situation.

Third, the study relies on self-reported practices. What doctors say they do in interviews may not perfectly match what actually happens in their clinics. However, the consistency of themes across diverse practice settings (academic and community, multiple geographic regions) lends credibility to the findings.

Finally, the sample size is small (10 participants), which is typical and appropriate for qualitative research but means the findings should not be overgeneralized.

## Recommendations for Patients and Families

Based on the expert insights from this study, here are practical recommendations for patients considering or currently receiving bispecific antibody therapy:

1.
**Understand the treatment schedule.** Bispecific antibodies begin with step-up dosing — a gradual dose increase over the first weeks of treatment. This is when CRS is most likely to occur, so closer monitoring (either in the hospital or in an outpatient infusion center with rapid response capability) is standard.
1.
**Know the symptoms of CRS.** Fever, chills, low blood pressure, and difficulty breathing should be reported immediately. Early intervention — including tocilizumab — makes these events much more manageable.
1.
**Be aware of neurological symptoms (ICANS).** Confusion, difficulty finding words, tremors, or unusual behavior warrant urgent medical attention, especially during early treatment cycles.
1.
**Stay on top of infection prevention.** Ask your care team about antiviral prophylaxis, PJP prophylaxis, and IVIG replacement. Most doctors recommend monitoring immunoglobulin levels regularly. Even if you don't have low white blood cell counts, your immune system is still suppressed — so report fevers or signs of infection promptly.
1.
**If you're receiving a GPRC5D-targeted bispecific, expect skin, nail, mouth, and taste changes.** These are different from the side effects of BCMA-targeted agents and primarily affect quality of life. Ask about supportive care options — topical treatments, mouth rinses, nutritional support, and taste management strategies can help.
1.
**Facilitate communication between your care teams.** Ask for a written summary of your treatment plan, dosing calendar, and infection prophylaxis plan. Make sure your local oncologist knows exactly who to contact at the academic center if a problem arises.
1.
**Discuss blood count management.** Low neutrophils (neutropenia) are common, especially early in treatment. Growth factor support can help. Ask your doctor about monitoring frequency.
1.
**Plan for the long term.** Side effects like low blood counts may improve over weeks to months. Infections are the main long-term challenge. Regular monitoring and proactive supportive care are essential to staying on therapy successfully.
1.
**Engage your caregivers.** The study emphasized that caregiver support is critical — particularly for recognizing neurological symptoms early and for helping with practical aspects of treatment navigation.
1.
**Ask about clinical trials and sequencing.** If your doctor is deciding between BCMA- and GPRC5D-targeted agents, ask about the rationale based on your prior therapies and your doctor's goals for your treatment. Tumor boards and multidisciplinary discussions help inform these decisions.

## Frequently Asked Questions

### What are bispecific antibodies and who are they for?

Bispecific antibodies are engineered proteins that grab two targets at once: CD3 on the immune system's killer T cells and a marker on myeloma cells, usually BCMA or GPRC5D. This redirects the body's own immune system to attack malignant plasma cells. In interviews, ten blood cancer specialists described them as effective for relapsed/refractory multiple myeloma, including disease resistant to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies.

### What is cytokine release syndrome (CRS) and how serious is it?

CRS is the most common short-term side effect. Activated immune cells release inflammatory proteins, causing fever, chills, low blood pressure, and sometimes breathing difficulty. In interviews, ten specialists said CRS was usually mild and appeared early, mostly during step-up dosing. It is managed with close monitoring and early tocilizumab, a medication that blocks cytokine signaling. Some academic programs now give tocilizumab preventively so step-up dosing can happen in outpatient settings.

### What is ICANS and what should I watch for?

ICANS is a neurological side effect that can cause confusion, difficulty speaking, tremors, or other symptoms. In interviews, ten specialists described it as less common than CRS but requiring extra attention, especially during initial dosing. Early detection through close neurological monitoring and staff awareness was emphasized, along with caregiver support. Report confusion, word-finding trouble, tremors, or unusual behavior urgently, particularly during early treatment cycles.

### Why are infections such a big concern with this treatment?

In interviews, ten specialists called infections the most challenging long-term issue. Bispecific antibodies targeting BCMA deplete plasma cells, including healthy ones that make protective antibodies, so patients often develop low immunoglobulin levels. Infections occurred even without low neutrophil counts. Prevention includes antiviral prophylaxis, PJP prophylaxis, IVIG replacement, and regular immunoglobulin monitoring. Doctors said IVIG significantly reduces infection rates but does not eliminate them, so report fevers promptly.

### Will I need to travel for treatment, or can I stay local?

It depends on your center. In interviews, ten specialists described two shared-care models: academic centers do step-up dosing and early monitoring, then hand maintenance to your local oncologist, or the academic center stays involved through check-ins and consultation. Community practices often lack hospital support for step-up dosing. Ask who monitors you during ramp-up, who handles problems afterward, and exactly who to call.

### What side effects are specific to GPRC5D-targeted bispecific antibodies?

In interviews, ten specialists said GPRC5D-targeted agents cause more skin reactions, nail changes, mouth issues, and taste changes than BCMA-targeted agents. These are distinct from BCMA side effects and mainly affect quality of life and nutrition. They usually need counseling and supportive care rather than acute intervention. Ask your team about topical treatments, mouth rinses, nutritional support, and taste management strategies if you receive a GPRC5D-targeted bispecific.

### How can I help my local doctor and academic center communicate?

In interviews, ten specialists said electronic health record fragmentation complicates shared care, and communication quality varied. As a patient or caregiver, ask for a written summary of your treatment plan, dosing calendar, and infection prophylaxis plan. Confirm your local oncologist receives these and knows who to contact at the academic center. Understand the escalation pathway: exactly who to call and when if symptoms appear between visits.

### When should a patient with relapsed/refractory multiple myeloma considering bispecific antibody therapy seek a second opinion?

A second opinion can help when the choice between a BCMA-targeted and a GPRC5D-targeted bispecific antibody is unclear, since no head-to-head comparison studies exist and selection is based on prior therapy exposure and treatment goals. It can also help when deciding between inpatient and outpatient step-up dosing, or when planning a transition to CAR T-cell therapy. Because infections are the main long-term challenge and supportive care practices vary between centers, an independent review of prophylaxis and monitoring plans is reasonable. Diagnostic Detectives Network provides independent expert second opinions.

## Source Information

This patient-friendly article is based on peer-reviewed research (preprint version) originally titled *"Practical Management of Adverse Events Associated with Bispecific Antibodies for the Treatment of Multiple Myeloma: A Qualitative Interview Study"*.

**Authors:** Tisheeka R. Graham, PhD, MPH; Michael White, PhD; Brandon Blue, MD; Monique Hartley-Brown, MD, MMSc; Bradley D. Hunter, MD; Chanh Huynh, MD; Nisha Joseph, MD; Amany Keruakous, MD, MS; Darren Pan, MD; Priya Rudolph, MD, PhD; Rishi Sawhney, MD; Attaya Suvannasankha, MD

**Publication details:** medRxiv preprint doi: https://doi.org/10.64898/2026.04.24.26350878; posted April 27, 2026. This version has not been certified by peer review and should not be used to guide clinical practice.

**Support:** The study was supported by an independent educational grant from Janssen Biotech.

**Institutional affiliations:** Medlive-A PlatformQ Health Brand (Needham, MA); H. Lee Moffitt Cancer Center and Research Institute (Tampa, FL); Dana-Farber Cancer Institute (Boston, MA); Intermountain Health (Salt Lake City, UT); Cancer Care Associates of York (York, PA); Emory University School of Medicine (Atlanta, GA); Augusta University (Augusta, GA); University of California, San Francisco (San Francisco, CA); Georgia Cancer Specialists (Athens, GA); Bayhealth Hematology/Oncology Associates (Dover, DE); Indiana University School of Medicine (Indianapolis, IN).

*Note: This patient-friendly translation summarizes the original research for educational purposes. Individual treatment decisions should always be made in consultation with your healthcare team.*


---
Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay.
Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact
Canonical page: https://diagnosticdetectives.com/products/understanding-and-managing-side-effects-of-bispecific-antibody-therapy-for-multiple-myeloma-what-patients-should-know